ClinicalTrials.gg

Program

tovorafenib

Also written as “Tovorafenib”, “MLN2480” and “TAK-580”.

Its studies are mostly in Melanoma, led by 3 companies.

Furthest: phase 3, since Sep 16, 20228 company-led studies, 3 open or runningNext primary completion: May 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Day One Biopharmaceuticals42 open or runningphase 3since Sep 16, 2022Feb 3, 2021May 31, 2027phase 2 · NCT04775485
Takeda30 open or runningphase 1since Aug 26, 2011Aug 26, 2011none ahead
Ipsen11 open or runningphase 1since Feb 17, 2026Feb 17, 2026Jul 31, 2030phase 1 · NCT07441707

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 26, 2011First study: phase 1 study in MelanomaNew to TakedaTakeda · NCT01425008 · 149 enrolled · United States, United Kingdom
  2. Dec 23, 2014Phase 1 study in Advanced Nonhematologic MalignanciesTakeda · NCT02327169 · 81 enrolled · United States, France, Spain and more
  3. Mar 25, 2016Phase 1 study in MelanomaTakeda · NCT02723006 · 22 enrolled · United States
  4. Feb 3, 2021Day One Biopharmaceuticals's first study: phase 2 study in Low-grade GliomaNew to Day One BiopharmaceuticalsDay One Biopharmaceuticals · NCT04775485 · 141 planned · United States, Australia, Canada and more
  5. Jun 23, 2021Phase 2 study in MelanomaDay One Biopharmaceuticals · NCT04985604 · 23 enrolled · United States, Australia, Belgium and more
  6. Sep 16, 2022Phase 3 study in Noonan Syndrome 5Day One Biopharmaceuticals · NCT05566795 · 418 enrolled · United States, Australia, Austria and more
  7. Jul 3, 2025Phase 1 study in MelanomaDay One Biopharmaceuticals · NCT07121829 · 44 enrolled · United States, Canada
  8. Feb 17, 2026Ipsen's first study: phase 1 study in Low-grade GliomaNew to IpsenIpsen · NCT07441707 · 6 enrolled · Japan

Ahead

  1. May 31, 2027Primary completion: phase 2 study in Low-grade GliomaDay One Biopharmaceuticals · NCT04775485
  2. Jun 2027Primary completion: phase 3 study in Noonan Syndrome 5Day One Biopharmaceuticals · NCT05566795
  3. Jul 31, 2030Primary completion: phase 1 study in Low-grade GliomaIpsen · NCT07441707

TargetBeta

“RAF serine/threonine protein kinase inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
belvarafenibruleHanmi Pharmaceuticalphase 26

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07441707Low-grade Glioma · Japan1Active, not recruitingIpsenJul 31, 20306
NCT07121829Melanoma · United States, Canada1TerminatedDay One BiopharmaceuticalsDec 18, 202444
NCT05566795Noonan Syndrome 5 · United States, Australia, Austria and more3Active, not recruitingDay One BiopharmaceuticalsJun 2027418
NCT04985604Melanoma · United States, Australia, Belgium and more2TerminatedDay One BiopharmaceuticalsJul 8, 202423
NCT04775485Low-grade Glioma · United States, Australia, Canada and more2RecruitingDay One BiopharmaceuticalsMay 31, 2027141
NCT02723006Melanoma · United States1TerminatedTakedaMay 11, 201822
NCT02327169Advanced Nonhematologic Malignancies · United States, France, Spain and more1CompletedTakedaJul 2, 201881
NCT01425008Melanoma · United States, United Kingdom1CompletedTakedaApr 11, 2017149

How it is read

Names in the registry

  • “Tovorafenib”, 5 entries
  • “MLN2480”, 2 entries
  • “TAK-580”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.